|
Title
|
|
|
|
Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcome
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Introduction: We investigated the predictive value of standard neurological evaluation, a commercially available biomarker assay and neuroimaging in the subacute phase for outcome after thrombolytic therapy in ischemic stroke. Methods: Thirty-four consecutive ischemic stroke patients were evaluated by means of the NIH Stroke Scale (NIHSS72), the Triage® Stroke Panel (MMX72) and standardized infarct volumetry at 72 h after treatment with intravenous recombinant tissue plasminogen activator or intra-arterial urokinase. Outcome was assessed by the modified Rankin Scale (mRS) at 3 months after the stroke. Results: NIHSS72, MMX72 and infarct volume correlated significantly with the mRS score at month 3 and emerged as independent outcome predictors from logistic regression analysis. NIHSS72 is the best predictor for outcome, but its accuracy increases by 9 and 6% when combined with MMX72 and infarct volumetry, respectively. The combined use of NIHSS72 and MMX72 allows long-term outcome prediction with 97% accuracy, which is not further improved by infarct volumetry. Conclusions: Routine clinical evaluation, bedside testing of biochemical markers by the Triage Stroke Panel and infarct volumetry on neuroimaging at 72 h after thrombolytic therapy are predictors for long-term outcome of ischemic stroke patients. Clinical assessment is the most reliable parameter for outcome prediction, but its predictive value is substantially improved when combined with the biomarker panel. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
European neurology. - Basel
| |
|
Publication
|
|
|
|
Basel
:
2009
| |
|
ISSN
|
|
|
|
0014-3022
| |
|
Volume/pages
|
|
|
|
62
:1
(2009)
, p. 9-15
| |
|
ISI
|
|
|
|
000266343000002
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|